DOI: 10.1007/s13311-016-0496-5 Pages: 256-264
Article Type: Review

Toward Personalized Targeted Therapeutics: An Overview

1. University of Texas MD Anderson Cancer Center, Department of Neuro-Oncology

2. National Institutes of Health, Neuro-Oncology Branch, National Cancer Institute

Correspondence to:
Shiao-Pei S. Weathers
Email: sweathers@mdanderson.org

Close

Abstract

In neuro-oncology, there has been a movement towards personalized medicine, or tailoring treatment to the individual patient. Ideally, tumor and patient evaluations would lead to the selection of the best treatment (based on tumor characterization) and the right dosing schedule (based on patient characterization). The recent advances in the molecular analysis of glioblastoma have created optimism that personalized targeted therapy is within reach. Although our understanding of the molecular complexity of glioblastoma has increased over the years, the path to developing effective targeted therapeutic strategies is wrought with many challenges, as described in this review. These challenges include disease heterogeneity, clinical and genomic patient variability, limited number of effective treatments, clinical trial inefficiency, drug delivery, and clinical trial support and accrual. To confront these challenges, it will be imperative to devise innovative and adaptive clinical trials in order to accelerate our efforts in improving the outcomes for our patients who have been in desperate need.

To access the full text, please Sign in

If you have institutional access, please click here

  • Online: Dec 19, 2016

Article Tools